Multimodal imaging-defined subregions in newly diagnosed glioblastoma: impact on overall survival. Issue 2 (22nd October 2018)

• Record Type: Journal Article
• Authors: John, Flóra; Bosnyák, Edit; Robinette, Natasha L; Amit-Yousif, Alit J; Barger, Geoffrey R; Shah, Keval D; Michelhaugh, Sharon K; Klinger, Neil V; Mittal, Sandeep; Juhász, Csaba
• Is Part Of: Neuro-oncology. Volume 21:Issue 2(2019)
• Page Start: 264
• Page End: 273
• Publication Date: 2018-10-22
• Subjects: glioblastoma -- diffusion-weighted imaging -- positron emission tomography -- amino acid -- survival; Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noy169
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: Background: Although glioblastomas are heterogeneous brain-infiltrating tumors, their treatment is mostly focused on the contrast-enhancing tumor mass. In this study, we combined conventional MRI, diffusion-weighted imaging (DWI), and amino acid PET to explore imaging-defined glioblastoma subregions and evaluate their potential prognostic value. Methods: Contrast-enhanced T1, T2/fluid attenuated inversion recovery (FLAIR) MR images, apparent diffusion coefficient (ADC) maps from DWI, and alpha-[ 11 C]-methyl-L-tryptophan (AMT)-PET images were analyzed in 30 patients with newly diagnosed glioblastoma. Five tumor subregions were identified based on a combination of MRI contrast enhancement, T2/FLAIR signal abnormalities, and AMT uptake on PET. ADC and AMT uptake tumor/contralateral normal cortex (T/N) ratios in these tumor subregions were correlated, and their prognostic value was determined. Results: A total of 115 MRI/PET-defined subregions were analyzed. Most tumors showed not only a high-AMT uptake (T/N ratio > 1.65, N = 27) but also a low-uptake subregion ( N = 21) within the contrast-enhancing tumor mass. High AMT uptake extending beyond contrast enhancement was also common ( N = 25) and was associated with low ADC ( r = −0.40, P = 0.05). Higher AMT uptake in the contrast-enhancing tumor subregions was strongly prognostic for overall survival (hazard ratio: 7.83; 95% CI: 1.98–31.02, P = 0.003), independent of clinical and molecular genetic prognostic variables. Nonresected high-AMT uptake subregions predicted the sites of tumor progression on posttreatment PET performed in 10 patients. Conclusions: Glioblastomas show heterogeneous amino acid uptake with high-uptake regions often extending into non-enhancing brain with high cellularity; nonresection of these predict the site of posttreatment progression. High tryptophan uptake values in MRI contrast-enhancing tumor subregions are a strong, independent imaging marker for longer overall survival.